Epidemiological description and analysis of RdRp, E and N genes dynamic 1 by RT-PCR of SARS-CoV-2 in Moroccan population: Experience of the 2 National Reference Laboratory (LNR)-UM6SS 3 Benrahma houda^{1,2}*, Diawara Idrissa^{2,3}, Smyej Imane², Rahoui Jalila ², Meskaouni Nida², 4 Benmessaoud Rachid², Arouro Khadija², Jaras Khadija², Moujid Fatima Zahra², Adam 5 Zahra², Nahir Salma², Aouzal Zineb², Elguezzar Hajar², Jeddane Leila², Ousti Fadoua², EL 6 Bakkouri Jalila^{2,4}, Nejjari Chakib⁵ 7 8 1 - Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, 9 10 Morocco. 11 2 -National Reference Laboratory, Mohammed VI University of Health Sciences (UM6SS), 12 Casablanca, Morocco. 3- Faculty of Nursing and Allied Health Sciences, Mohammed VI University of Health Sciences 13 (UM6SS), Casablanca Morocco 14 4-Laboratory of Clinical Immunology, Inflammation and Allergy (LICIA), Faculty of Medicine and 15 Pharmacy, Hassan II University, Casablanca, Morocco. 16 5-International School of Public Health, Mohammed VI University of Health Sciences (UM6SS), 17 Casablanca, Morocco. 18 19 * Corresponding author: hbenrahama@um6ss.ma 20 21 22 23 24 25 26 27 28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

30

34

35

36

39

31 The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome

32 coronavirus 2 (SARS-CoV-2), is a new infectious disease that first emerged in Hubei

province, China, in December 2019. On 2 March 2020, the Moroccan Ministry of Health

confirmed the first COVID-19 case in Morocco. The new virus SARS-CoV-2 was identified

in the sample of a Moroccan expatriate residing in Italy. Without a therapeutic vaccine or

specific antiviral drugs, early detection and isolation become essential against novel

37 Coronavirus.

This study aims to analyze the epidemiological profile of the SARS-CoV-2 in Moroccan cases

and to investigate the dynamic of RdRp, N, and E genes in patients from diagnosis until the

40 recovery.

41 Among 859 COVID-19 RT-PCR tests realized for 376 patients, 187 cases had positive results

42 COVID-19. 4% were positive with the 3 genes *RdRp*, *N*, and *E*, 40 % with *N* and *E* genes, 3%

with RdRp and N genes, 31% with only the RdRp gene and 22% cases are positives

with N gene. The analysis of the Covid-19 genes (RdRp, N, and E) dynamic reveal that more

45 than 6% stay positive with detection of the N and E gene, and 14% with the N gene after 12

46 days of treatment.

47 The median period from positive to the first negative Covid-19 RT-PCR tests was 6.8±2.24

days for 44% cases, 14.31 ± 2.4 days for 30%, and 22.67 ± 1.21 days for 4%.

49 This a first description of the Moroccan COVID-19 cases and the analysis of the dynamic of

50 the RdRp, N, and E genes. The analysis of our population can help to improve in the care of

51 patients.

52

53

54

55

56

57

58

59

Keywords: COVID-19, SARS-CoV-2, *RdRp* gene, *N* gene, *E* gene, RT-PCR, Morocco.

1. Introduction

- According to the World Health Organization (WHO), the WHO China Country Office was
- 62 informed of cases of pneumonia of unknown etiology in Wuhan City, Hubei Province, on
- 63 December 31, 2019 [1].
- The investigations identified a new virus that was closely related to severe acute respiratory
- 65 syndrome coronavirus (SARS -CoV) [2]. The novel coronavirus in humans was initially
- named as 2019-nCoV [3], and then designated as SARS-CoV-2 by the Coronavirus Study
- 67 Group of the International Committee on Taxonomy of Viruses [4]. And WHO announced the
- epidemic disease caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19) [5].
- 69 On April 28th, 2020, 213 countries and territories included Morocco, with more than 2
- 70 959 929 confirmed cases and more than 202 733 have died from the rapidly-spreading SARS-
- 71 CoV-2 virus [6].
- On the 2sd of March 2020, the Ministry of Health confirmed the first COVID-19 case in
- 73 Morocco. The virus was detected in a Moroccan expatriate residing in Italy and who came
- from Italy on February 27th, 2020. Also, the second case was confirmed by the end of the
- same day, involving an 89-year-old woman Moroccan residing in Italy too who had returned
- to Morocco on the 25th of February 2020. Till the 28th of April 2020, 4,246 confirmed cases of
- 77 COVID-19 with 163 deaths [7].
- Among the foremost priorities to facilitate public health interventions in Morocco is a reliable
- 79 laboratory diagnosis. For that, the Ministry of Health expands screening tests across the
- 80 country as part of the country's preparation to end confinement measurement and to rapidly
- evaluate more possible cases. On April 1st, 2020, the National Reference Laboratory (LNR) of
- 82 Mohammed VI University of Health Sciences (UM6SS), became the fourth laboratory in
- 83 Morocco authorized to carry out the biological screening and diagnostics of COVID-19.
- 84 In acute respiratory infection, RT-PCR is routinely used to detect causative viruses from
- respiratory secretions. For ensuring the diagnostic of Covid-19, the LNR has been equipped
- with different platforms to performed real-time RT-PCR testing for three targets in the virus:
- the envelope (E), the RNA dependent RNA polymerase (RdRp) and the nucleocapsid (N).
- 88 The coronavirus SARS-CoV-2 genome consists of a leader sequence, ORF1ab encoding
- 89 proteins for RNA replication, and genes for non-structural proteins (nps) and structural
- 90 proteins [8]. Like other betacoronaviruses, the SARS-CoV-2 genome encodes four major

- 91 structural proteins. The structural proteins are involved in various viral processes, including
- 92 virus particle formation. The structural proteins include spike (S), envelope (E), membrane
- protein (M), and nucleoprotein (N), which are common to all coronaviruses [9, 10].
- To date, no studies exploring the variation of RdRp, N and E genes expression of SARS-CoV-
- 2 in the patient's specimen. In this study, in first time, we analyses the epidemiological profile
- of the SARS-CoV-2 in Moroccan cases and in second time we explored the dynamic of *RdRp*
- 97 , N and E genes in patients from diagnosis until the recovery.

2. Material and Methods

2.1.Patients and samples

- All samples included in this study were routinely tested for the presence of SARS-CoV-2
- immediately upon arrival in the National Reference Laboratory (LNR) from the Cheikh
- 103 Khalifa International University Hospital, Mohammed VI University of Health Sciences
- 104 (UM6SS). In this study, we included a total of 376 patients admitted to hospital between
- 105 March 28, 2020, and April 29, 2020.
- Nasopharyngeal swab samples were collected for extracting SARS-CoV-2 RNA from patients
- suspected of having COVID-19 infection. The collected swabs were placed into the transport
- tube where includes a universal transporting medium that is room temperature stable (UTM-
- 109 RT).

98

99

100

- 110 The LNR provide a RT-PCR to clinically suspected COVID-19 patients when they were
- admitted. Multiple repeat RT-PCR tests were performed during admission in the hospital in a
- different period based on national mandatory management guidelines.

2.2.RNA extraction

- 114 The RNA extraction from nasopharyngeal samples was performed using AccuPrep ® Viral
- 115 RNA Extraction Kit (Bioneer Corporation, Korea) according to the manufacturer's
- instructions. Briefly, swabs were vortexed for 10 second speed followed by extraction from
- 117 200 μl of UTM-RT, and all samples were subjected to extraction with an elution volume 50
- 118 μl.

119

120

2.3.RT-PCR SARS-CoV2 detection

One-Step Reverse Transcription Real-Time polymerase chain reaction (RT-PCR) was used to confirm the presence of the SARS-CoV-2 genome by amplification of *RdRp*, E, and N gene. For the samples included in this study, we realized the RT-PCR by using GeneFinderTM COVID-19 Plus RealAmp Kit according to the manufacturer's protocol (OSANG Healthcare Co., Ltd, South Korea).

The RT-PCR assays were performed on the CFX96 Touch Real-Time PCR Detection System

129 (Bio-Rad Laboratories, Inc.). The reaction mixture contains 10 μl of COVID-19 PLUS
 130 Reaction Mixture, 5μl of COVID-19 PLUS Probe Mixture, and 5μl of sample RNA. Total

131 Reaction volume is 20µl per sample.

The RT-PCR assays were performed under the following conditions: reverse transcriptional reaction at 50 °C for 20 minutes, pre- denaturation at 95 °C for 5 minutes, 45 cycles of denaturation at 95 °C for 15 seconds and extending and collecting fluorescence signal at 58 °C for 60 seconds.

The result interpretation was performed according to the manufacturer's protocol (table 1)

<u>Table 1</u>: Results interpretation of GeneFinderTM COVID-19 Plus RealAmp Kit

Results Of RT-PCR	Ct range			
	RdRp	E	N	IC
	≤ 43	≤ 43	≤ 43	≤ 35
COVID-19 Positive	≤ 4 3	≤ 43	U.D	≤ 35
	≤ 43	U.D	≤ 43	≤ 35
COVID-19 Positive if RdRp ≤ 43 after the second test	≤ 43	U.D	U.D	≤ 35
COVID-19 Positive if E and $N \le 43$ after the second test	U.D	≤ 43	≤ 43	≤ 35
COVID-19 Positive if $N \le 43$ after the second test	U.D	U.D	≤ 43	≤ 35
Beta coronavirus	U.D	≤ 43	U.D	≤ 35

Negative	U.D	U.D	U.D	≤ 35

U.D= undetermined, Ct: Cycle Threshold, IC: Internal Control

2.4. Statistical analysis

- 140 Continuous variables were presented as means \pm standard deviation (SD). For categorical
- variables were presented as counts and percentages. P-values less than 0.05 were considered
- as statistically significant. All statistical analyses were performed using STATA software,
- 143 version 11.0.

138

139

144

145

157

3. Results

3.1.General characteristics

- In this study, the total number of Covid-19 RT-PCR assays realized on the 376 included
- 147 COVID-19 patients was 859, with 3.7 tests per patient. The mean age was 46.82 ± 20.54 years
- old, comprising 55.76 % men and 44.24% women (table 2).
- Of the 376 patients, 189 (50.3 %) had negative results and 187 (49.7%) had positive results
- for Covid-19 RT-PCR tests. In the negative cases, the men present 53.16%, and the women
- 151 46.84% (table 2).
- In the Covid-19 positives cases, the gender distribution is 41.83% women and 58.14% men.
- Among the Covid-19 positive patients, we identify 129 sporadic and 58 family cases (with
- known exposure history). Family with SARS-CoV-2 infection corresponds to 24 families.
- The analysis of these families showed that 71% included 2 cases, 21% included 3 cases, 4%
- included 4 cases, and 4% included 5 cases,

3.2.SARS-CoV-2 Genes dynamic

- The interpretation of the RT-PCR results for the first diagnosis of the three genes RdRp, N,
- and E showed that: 4% of cases are positive with the 3 genes RdRp, N, and E. 31% cases are
- positive with only the *RdRp* gene, 3% of cases are positive with *RdRp* and *N* gene, 22% cases
- are positive with N gene, and 40 % with N and E gene. (tab2)
- The analysis of the Covid-19 genes *RdRp*, *N*, and *E* dynamic revealed that more than 6% of
- the SARS-CoV-2 infected person stay positive with detection of the N and E gene, and 14%
- of the positive patients stay positive with the N gene after 12 days the treatment. After more
- than 21 days of treatment, the RT-PCR test reveals the persistence of the N gene in 4 cases
- 166 (3%).

From symptoms and positive Covid-19 RT-PCR test to the first negative Covid-19 RT-PCR tests, the median period was 6.8±2.24 days for 44% cases.

For 30% cases the median period 14.31 ± 2.4 days for. A longer period was identified in 4% of cases with a median period of 22.67 ± 1.21 days. For 22% of cases the median period was 2.03 ± 0.88 days, for these patients the RT-PCR was realized for the first time by other reference laboratories (tab2). For all patients with the first negative test for the 3 genes, a second RT-PCR test was realized after 24h (table 2).

We also investigate the impact of age on the profile of Covid-19 by RT-PCR. The Test of homogeneity is carried out by comparing the positive and negative cases for a different range of age. A significant association was observed for the over than 64 years old range with p = 0.009 and OR = 1.74, 95% CI = [1.28, 2.33].

Table 2: clinical characteristics of all patients, and gene dynamic in positives cases

Variable	All patients
Clinical parameters	
Gender (%)	
Men	55.76
Women	44.24
Age (mean \pm SD) years	46.82 ± 20.54
SARS-CoV-2 RT-PCR assay	
Total tests	859
Tests/patient	3.75 /patient
Positive tests	187
Sporadic positive cases	129
Families positive cases	58
Onset of symptom to negative test, median period	d
(days)	
For 44% cases	6.8±2.24 days
For 30% cases	14.31± 2.4 days
For 22% cases	$2.03 \pm 0.88 \text{ days}$
For 4% cases	22.67± 1.21 days
Gene dynamic after days treatment (133 cases)	Positives cases %
After 12 days	
Presence N and E gene	16
Presence N gene	14
After 21	
N gene	3

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

4. Discussion The current SARS-CoV-2 outbreak is the third epidemic attributed to coronavirus in the 21st century, and incredibly the number of confirmed SARS-CoV-2 infection has surpassed SARS and MERS in world wild [1, 11]. This is the first scale report from 285 COVID-19 Moroccan patients with 859 samples of RT-PCR tests for Covid-19 detection. The data of this study is the preliminary analysis of the Moroccan population analyzed in the LNR which will allow making more in-depth studies of patients infected by the SARS-CoV-2. After analysis of the cases implicated in our study, we found that the infection was prone to affect mem more than women with different percentages of 55.76% and 44.24% respectively. This result consistent with many conclusions from different studies [12, 13]. Many studies suggested that coronavirus infected older more than young individuals [14]. In our study, comparing positive and negative cases for a different range of age we found a significate difference (p = 0.009 and OR= 1.74, 95% CI= [1.28, 2.33]), for the range age ≥ 64 years. Various studies confirm our observation which suggests that older individuals are more likely to be infected by the virus [12, 15]. We can explain the correlation between age and virus by the presence of higher levels of angiotensin converting enzyme 2 in older people alveoli which are thought to be a receptor for SARS [16]. This study included 129 sporadic and 58 familial cases. Various studies analyses the mechanism of transmission of SARS-CoV-2, and they confirmed that the Human to Human transmission via droplets is the main route of transmission within a susceptible population. But no rule out transmission by asymptomatic carriers [17]. The first cases in Morocco were traveled from the epidemic region in Italy. And family members who traveled from Europe were most likely responsible for a familial cluster of COVID-19 once back home. Another explication of the presence of clusters in our country is the organization of familial activity (wedding, death ceremonies, etc...), and some industrial activity. The SARS-Cov-2 share similar sequencing characteristics with SARS-CoV and MERS-CoV, but the analysis of different case series showed that the shedding pattern of the viral nucleic

acid of patients infected with SARS-CoV-2 is different from SARS-CoV. In the early stage, 210 the SARS-CoV had a modest viral load peaked approximately 10 days after symptoms onset. 211 For the SARS-CoV-2, the median duration of the virus in the respiratory sample was 18 days, 212 213 and from symptom onset, the peak viral shedding in respiratory specimens of positive cases 214 occurred after about 10 to days for the SARS-CoV [18, 19]. In our study, we found that the 215 duration of virus shedding in lower respiratory tract samples was longer than 14 days for 30% 216 of cases, and peak viral shedding occurred after about two weeks from symptom onset. 217 Tracing the duration of the virus is very important for effective control and prevention of the epidemic. 218 Because highly sensitive and specific diagnostic assays are the key to the identification of 219 cases, contact tracing, for diagnosis of cases with suspected SARS-CoV-2 infection. We 220 chose to performed detection of unique viral sequences with RT-PCR by using 221 GeneFinderTM COVID-19 Plus RealAmp Kit (OSANG Healthcare Co., Ltd, South Korea), 222 which is one of the validated protocols for in vitro diagnostic (CE marked) available on the 223 market. The RT-PCR assays target the E gene encoding for the envelope protein, which is 224 common to the Sarbecovirus subgenus, the second specific assay targets the RdRp gene 225 encoding for RNA-dependent RNA polymerase and the third assay target the N gene encoding 226 227 nucleocapsid protein [20, 21]. 228 Based on the RT-PCR tests of positive cases during hospitalization period, we found that after 12 days of treatment, more than 6% of the SARS-CoV-2 infected person stay positive with 229 the detection of the N and E gene, and 14% of the positive patients stay positive with 230 the N gene. And only 3% stay positive with the N gene after more than 21 days of treatment. 231 To our knowledge, the dynamic of the three SARS-CoV-2 genes was not analyzed before. 232 The genome SARS-CoV-2 shares similar sequencing characteristics with SARS-CoV and 233 MERSCoV. Human coronaviruses are positive-sense RNA (30 kb) viruses. Two types of 234 proteins characterize Human coronavirus, structural (Spike (S), Nucleocapsid (N), Matrix 235 236 (M), and Envelope (E)) and non-structural proteins (nsp1 up to nsp16) including the RNA 237 dependent RNA polymerase (RdRp) (nsp12). The organization of the coronavirus genome is 238 5'-leader-UTR- replicase-S (Spike)-E (Envelope)-M (Membrane)- N (Nucleocapsid)-3' UTRpoly (A) tail [22]. 239 If we analyze the Coronavirus life cycle, we found that the initial attachment of the virion to 240

the host cell is initiated by interactions between the S protein and its receptor. Following

receptor binding, the virus must next gain access to the host cell cytosol. This is generally accomplished by acid dependent proteolytic cleavage of S protein [23]. The RdRp is a vital enzyme for the life cycle of RNA viruses, because the ability of coronavirus to recombine is tied to the strand switching ability of this protein. Recombination likely plays a prominent role in viral evolution [23]. For the nucleocapsid (N) protein, the primary function is to package the viral RNA genome within the viral envelope into a ribonucleoprotein (RNP) complex called the capsid. Ribonucleocapsid packaging is a fundamental part of viral self-assembly and replication. Additionally, the N-protein of the SARS-CoV-2 affects host cell responses and may serve regulatory roles during its viral life cycle [24].

In our study, we found that the N gene persists in cases sample with $Ct \le 40$ in RT-PCR. To explain this persistence, different studies showed that the coronavirus N protein is abundantly produced within infected cells. And these proteins have multiple functions, including binding to viral RNA to form the ribonucleocapsid and have also been proposed to have roles in virus replication, transcription, and translation [24]. Also, in Humans cells, N proteins have been shown to cause deregulation of the cell-cycle, inhibit the production of interferon and induce apoptosis in serum deprived cells, of all which may have possible pathological consequences [24, 25].

5. Conclusion

In summary, this is the first description of the dynamic of *RdRp*, *N*, and *E* genes of the SARS-CoV-2 virus among COVID-19 positive patients. The study allow us to focus on several parameters involved in the care of patients. We highlighted that the comprehension of dynamism of these tree genes is an important parameter in the COVID -19 diagnosis. We plan to include in the second time the clinical parameters and the history of infection, to explain this dynamic of this infection. A comprehensive understanding of COVID-19 will help to control the disease.

Data Availability

All data underlying the results are available as part of the article, and no additional source data are required.

Declaration of Competing Interest

All authors declare that there are no conflicts of interest.

References

273

275

276

- World Health Organization (WHO). "Coronavirus. Geneva: WHO; 2020" [Accessed 28 april 2020]. Available from: https://www.who.int/health-topics/coronavirus.
- 280 2. P. Zhou, XL Yang, XG. Wang et al., "A pneumonia outbreak associated with a new coronavirus of probable 388 bat origin" Nature, vol.579, no. 7798, pp.270-273, 2020
- 3. A.E. Gorbalenya, S.C. Baker, R.S. Baric, et al., "The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" Nat Microbiol, vol.5, no.4, pp. 536–544, 2020.
- International Committee on Taxonomy of Virus "Naming the 2019 Coronavirus" 2020
 (https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1).
- 5. WHO,2020 "naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causesit"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
- 290 6. WHO, "Coronavirus disease 2019 (COVID-19) situation report 63". Coronavirus 291 Disease (COVID-2019), 2020.
- 7. https://www.sante.gov.ma/Pages/corona.aspx (Accessed 28 April 2020)
- 8. T. Li, Y. Zhang, L. Fu, et al., "siRNA targeting the leader sequence of SARS-CoV inhibits virus replication". Gene Therapy, vol.12, no.9, pp. 751–761, 2005.
- 9. M.A. Marra, S.J. Jones, C.R. Astell, et al., "The genome sequence of the SARS-associated coronavirus". Science, vol.300, no.7477, pp. 1399–1404, 2003.
- 10. Y. Ruan, C.L. Wei, A.E. Ling, et al., "Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection". The Lancet, vol. 361, no.361, pp. 1779–1785, 2003.
- 300 11. H. Ge, X. Wang, X. Yuan, et al., "The epidemiology and clinical information about COVID-19". Eur J Clin Microbiol Infect Dis, vol.9, n.1, pp.29, 2020.
- 12. N. Chen, M. Zhou, X. Dong, et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study" Lancet, vol.395, no.10223, pp. 507-513, 2020.
- 13. AT. Xiao, YX. Tong, C. Gao, et al. "Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study". J Clin Virol. Vol 11, pp.127:104346, 2020.
- 308 14. A. Badawi, SG. Ryoo. "Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis". Int J Infect Dis, vol. 49, pp, 129–33, 2016.
- 15. C. Huang, Y. Wang, X. Li, et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet, vol.395, no. 10223, pp. 497-506, 2020.

- 16. Y. Chen, K. Shan, W. Qian. "Asians Do Not Exhibit Elevated Expression or Unique 313
- Genetic Polymorphisms for ACE2, the Cell-Entry Receptor of SARS-CoV-2". Preprints 314 2020; 2020020258. 315
- 17. Y. Bai, L. Yao, T. Wei, et al. "Presumed asymptomatic carrier transmission of COVID-316 19". JAMA. 2020 [Epub ahead of print]. 317
- 318 18. IF. Hung, SK. Lau, PC. Woo, et al. "Viral loads in clinical specimens and SARS manifestations". Hong Kong Med J, vol.15, no. 9, pp.20-2, 2009. 319
- 19. L. Zhao, BK Jha., A. Wu, et al. "Antagonism of the interferon-induced OASRNase L 320 pathway by murine coronavirus ns2 protein is required for virus replication and liver 321 pathology". Cell Host Microbe, vol.11, no. 11, pp. 607–616, 2012. 322
- 323 20. M. Ciotti, S. Angeletti, M. Minieri, et al. "COVID-19 Outbreak: An Overview". Chemotherapy, vol. 7, pp. 1-9, 2020. 324
- 21. VM. Corman, O. Landt, M. Kaiser, et al. "Detection of 2019 novel coronavirus (2019-325 nCoV) by real-time RT-PCR". Euro Surveill, vol.25, no.3, pp. 2000045, 2020. 326
- 327 22. L. Zou, F. Ruan, M. Huang, et al. "SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients". N Engl J Med, vol.382, no.12, pp.1177-9, 2020. 328
- 23. A.R. Fehr, S. Perlman, "Coronaviruses: An Overview of Their Replication and 329 Pathogenesis". In: Maier H., Bickerton E., Britton P. (eds) Coronaviruses. Methods in 330 Molecular Biology, vol 1282. Humana Press, New York, NY, 2015. 331
- 24. R. McBride, M. Van Zyl, B.C. Fielding, "The Coronavirus Nucleocapsid Is a 332 Multifunctional Protein". Viruses, vol.6, no.8, pp. 2991-3018, 2014. 333
- 25. I Astuti, Ysrafil. "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): 334 An overview of viral structure and host response" .Diabetes Metab Syndr, vol.14, no.4, 335 pp.407-412, 2020.

336